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Background: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is
licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current
evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based
follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce
recurrence rates in this cohort.
Case presentation: Here we report an idiosyncratic reaction to sorafenib resulting in fatal hepatotoxicity and
associated renal failure in a 62 year-old man treated with sorafenib within the SORCE trial.
Conclusion: This is the first reported case of sorafenib exposure associated fatal toxicity in the adjuvant setting and
highlights the unpredictable adverse effects of novel adjuvant therapies.
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The current treatment of kidney cancer that has not
spread involves, when surgically feasible, the removal of
the affected kidney. When the tumour is very advanced
or particularly aggressive there is a high risk that despite
this procedure the cancer will recur either locally or in
another organ. For these individuals the current man-
agement is limited to observation of the patient and
treatment if recurrence is observed. The SORCE trial
aims to investigate whether giving these high-risk
patients sorafenib, a drug with anti-cancer activity in
kidney cancer that is known to have spread, will reduce
the recurrence rate. Here we report the case of a patient
on the SORCE trial who died from liver failure asso-
ciated with sorafenib treatment. Although this is an ex-
tremely uncommon occurrence, this case has important
implications in the treatment of patients who are* Correspondence: andrew.protheroe@oncology.ox.ac.uk
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reproduction in any medium, provided the orasymptomatic and may indeed be cancer free as well as
alerting clinicians to this rare adverse drug reaction.Case presentation
We describe the case of a previously fit 62 year-old man
who was diagnosed with RCC after presenting with new-
onset haematuria. His past medical history consisted of
isolated hypertension for which he took felodopine (5mg
OD) and bisoprolol (10mg OD). He was a former
smoker but had no other risk factors for, or a family his-
tory of, renal cancer. He had an open nephrectomy at
which there was no evidence of local or regional metas-
tases. The excised right kidney contained an 11cm diam-
eter clear cell RCC for which the Leibovitch score was 9
– a score associated with a 5 year metastasis free sur-
vival of 12.7% [1].
Sorafenib prolongs progression-free survival in
patients with advanced RCC who have failed other treat-
ments [2] and shows efficacy as a first-line agent [3].
Identification of treatments that reduce relapse rate or
extend disease-free remission is of utmost clinical im-
portance. The SORCE study is a phase III randomisedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role of adjuvant sorafenib in patients with resected pri-
mary renal cell carcinoma at intermediate or high risk of
relapse (Clinical trial identifier: NCT00492258). The pri-
mary outcome measure of this three-armed study is dis-
ease free survival; comparing those treated with
sorafenib for either 1 year or 3 years with placebo. Sec-
ondary outcome measures include metastasis-free sur-
vival, disease-specific survival time and overall survival.
Three months post- nephrectomy the patient was en-
rolled into the SORCE study. At this point he was well
and physically active and his blood parameters were
within normal range (Figure 1). He was commenced on
study medication which was later confirmed to be sora-
fenib 400mg BD. The initial 3 weeks of treatment were
free of adverse effects, but at week 4 he noted increasing
fatigue. By week 6 of treatment he had developed grade
1 mouth ulceration and grade 2 plantar erythrody-
saesthesia. Additionally he suffered malaise, with gastro-
intestinal discomfort and mild diarrhoea and had noted
an abdominal rash. He remained normotensive with a
normal full blood count, normal renal function and nor-
mal liver function. By week 7 of treatment his symptoms
worsened; with increasing fatigue, loss of appetite, nau-
sea, vomiting and diarrhoea. Treatment was withdrawn
but at this point jaundice developed. He had not noted
change in urine colour or volume, although he com-
plained of abdominal bloating and loose stools. There
was no history of fever but he was anorexic with
2kg weight loss. Apart from his prescription anti-
hypertensives and the sorafenib, he had taken no other
medications including antibiotics, statins or over-the-
counter analgesics. He had consumed no alcohol overFigure 1 Liver function tests on a temporal basis with the
period of sorafenib treatment shaded grey expressed as fold
increase on upper limit of normality. Bili: bilirubin, ALT: alanine
aminotransferose, AlkP: alkaline phosphatase, ULN: upper limit
normal.the study period and his previous alcohol consumption
was negligible. On examination, he was normotensive,
euvolaemic and was clearly jaundiced with non-tender
hepatomegaly. He was admitted to hospital at this point
for further management.
Investigations and management
Admission blood tests revealed an acute hepatitis with
an ALT 6935 (normal 10-45IU), bilirubin 288μM (3-
17μM), alkaline phosphatase 577IU (35-320IU) (Figure 1)
and a prothrombin time of 18.2s (n=12-15s). LDH was
markedly raised at 1226IU (n<260IU). The full blood
count was normal without leukocytosis whilst CRP was
moderately raised (34mg/dl, n<8mg/dl), a level that per-
sisted throughout treatment. His creatinine was moder-
ately raised at 201 μM, the baseline for this patient being
120-140 μM post-nephrectomy. An abdominal ultra-
sound demonstrated normal hepatic echogenicity with
normal calibre common bile duct and patent hepatic
vasculature. There was no obstructive uropathy. Viral
screening excluded acute cytomegalovirus and Epstein
Barr virus and hepatitis viruses. An immunology screen
was negative for ANA and ANCA but identified com-
plement consumption with reduced C3 (29mg/dl, 65-
190mg/dl) and C4 levels (13.6mg/dl, 14-40mg/dl). A
pyrexia of 37.9C was recorded on day 2 of admission
and the patient was given empirical ceftriaxone, although
a septic source was not identified and blood cultures were
uniformly negative. There followed marked deterioration
in hepatic and renal function with rising prothrombin
time refractory to Vitamin K and requiring repeated
plasma transfusions. On day 4, the patient became ence-
phalopathic and was transferred to the intensive care unit
where he was intubated. A repeat ultrasound revealed
mild peri-hepatic ascites which was subsequently found to
be transudative in nature. Further deterioration of renal
function precipitated initiation of continuous veno-venous
haemofiltration. Over the subsequent three days, despite
maximal supportive therapy including N-acetyl-cysteine,
there was progressive deterioration. His previous renal
tumour excluded him from candidacy for liver transplant.
Hypoglycaemia and lactataemia ensued and by day 7 the
prothrombin time had risen to >200s and serum ammo-
nium concentration was 120μmol/L (<35μmol), signifying
end-stage hepatic failure, and treatment was withdrawn.
At autopsy there was no evidence of metastatic dis-
ease. A terminal bronchopneumonia was noted although
organisms were not isolated. Histology of post-mortem
liver showed a lobular hepatitis with mononuclear cell
infiltrate and hepatocyte necrosis (Figure 2a, H&E stain).
Histology of the kidneys demonstrated acute tubular ne-
crosis with cellular debris and oxalate crystals within
tubules (2b, H&E stain) and collecting ducts (2c, H&E
stain). In addition, collecting ducts contained small
Figure 2 Histology of post-mortem liver showed a lobular hepatitis with hepatocyte necrosis (a, H&E stain). Histology of the kidneys
demonstrated acute tubular necrosis with cellular debris and oxalate crystals within tubules (b, H&E stain) and collecting ducts (c, H&E stain).
In addition, collecting ducts contained small numbers of myoglobin casts (d, immunoperoxidase stain).
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Conclusion
We believe the most likely cause of death to be an idio-
syncratic allergic reaction to sorafenib manifesting as
hepatotoxicity with associated renal impairment. This is
supported by a RUCAM causality score of 7, consistent
with sorafenib being the probable cause [4]. Drug
induced liver injury (DILI) is attributable to either direct
hepatotoxicity occurring soon after drug exposure, or a
delayed idiosyncratic reaction. Idiosyncratic drug reac-
tions are thought secondary to immune response, pos-
sibly to drug-protein haptens. They typically take 2–8
weeks to manifest and may demonstrate ongoing pro-
gression despite withdrawal of the offending drug [5,6].
Although sorafenib-induced hepatic dysfunction has
been previously described, this is the first description of
sorafenib-induced hepato-renal failure and represents
the first fatality in an individual otherwise systemically
well without underlying liver disease or known metasta-
ses. Sorafenib associated liver failure was first described
in a phase II trial for advanced thyroid cancer [7] where
the patient developed elevated LFTs 8 weeks after start-
ing sorafenib. Despite sorafenib withdrawal, hepatic
function worsened, culminating in death secondary to
hepatic failure. Sorafenib hepatotoxicity was likewisereported in a 65 year old female with underlying com-
pensated cirrhosis, secondary to non-alcoholic steatohe-
patitis, who received sorafenib as a third-line therapy for
advanced follicular thyroid carcinoma [8]. Treatment
was stopped after approximately 3 weeks when she
developed a skin rash with associated fever and flu-like
symptoms. At this point there was mild derangement of
hepatic function which progressed rapidly over the sub-
sequent 3 weeks, resulting in hospitalisation with a
hepatocellular picture of markedly raised trans-aminases.
A liver biopsy demonstrated drug-induced necrotic
hepatitis and the patient responded to treatment with
corticosteroids. Two further cases of sorafenib related
hepatotoxicity have also been described; in the treatment
of HCC [9], and also in an individual who had under-
gone cadaveric liver transplant for HCC [10]. However,
these cases differ in that LFTs became abnormal soon
after sorafenib administration (less than 5 days) and hep-
atic function normalised upon withdrawal of therapy.
The second of these cases had a liver biopsy demonstrat-
ing hyperallergic features with hepatic inflammatory in-
filtrate consistent with an immune mediated process
[10].
Genome wide association studies of DILI consistently
demonstrate susceptibility conferred by major histo-
compatibility complex (MHC) polymorphisms, support-
ing an immune basis to idiosyncratic DILI [11]. Although
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consistent HLA associations [12-14] similar HLA asso-
ciated hepatotoxicity has been noted to small molecule
kinase inhibitors. MHC associations have been reported
with susceptibility to lapatanib and pazopanib hepatotox-
icity [15,16]. Polymorphisms within HFE, the haema-
chromatosis gene residing within the extended MHC,
are associated with pazopanib toxicity; whilst lapatinib
toxicity is reproducibly associated with carriage of the
class II HLA allele HLA_DQA1*0201.
The case we describe showed a pronounced immunor-
esponse with elevated CRP, low-grade pyrexia, comple-
ment consumption and an immune infiltrate in the liver.
We suggest that this, coupled to a typical delay in onset
between commencing sorafenib and hepatic failure,
would support an immune mediated process. Given the
precedents shown with other DILI, a link to HLA sub-
type may be anticipated. Patterns of DILI tend to be
drug specific, with three phenotypes in terms of hepatic
dysfunction recognised. These being a hepatocellular
pattern, a cholestatic pattern and a mixed picture with
derangement in both trans-aminases and cholestasis but
neither picture predominating [6,17]. The pattern of
liver panel abnormalities in this case and the other 2
reported cases of delayed DILI to sorafenib would sug-
gest sorafenib can cause DILI with a hepatocellular pat-
tern of LFTs, with an ALT>3 x upper limit of normal
(ULN) and ratio of ALT/ULN: AlkP/ULN >5 between
3–7 weeks after initial exposure.
As with many idiosyncratic DILI, sorafenib hepatotox-
icity is uncommon. In phase III clinical trials of sorafe-
nib monotherapy the incidence of hepatic failure was
similar amongst sorafenib and placebo recipients [18].
Similarly, in two prospective phase III clinical trials of
sorafenib in patients with advanced HCC and mild liver
impairment (Child-Pugh A), the incidence of hepatic
failure and hepatic encephalopathy events were compar-
able between patients taking placebo (2.4% and 2.1%)
and sorafenib (2.5% and 1.8%) [19]. Likewise hepatic fail-
ure/encephalopathy events were not observed in a pla-
cebo controlled prospective phase III study in advanced
RCC (TARGET, n=903) [2]. Analysis of reported toxici-
ties from the SORCE trial supports the rarity of sorafe-
nib hepatotoxicity in the adjuvant setting, with this case
representing an idiosyncratic reaction as opposed to a
marked example of generalized hepatotoxicity (Meade
A., personal communication). Nonetheless, given that a
proportion of patients receiving sorafenib may have
impaired liver function due to HCC or metastatic dis-
ease, it is possible a delayed drug reaction to sorafenib
may be mistaken for, or coincide with disease progres-
sion. With this in mind it is noteworthy that, including
this case, all episodes of sorafenib-associated acute liver
failure have been reported outside HCC treatment.This case is the first documented death directly attrib-
utable to sorafenib in an otherwise well individual. Since
the patient had no evidence of metastatic disease prior
to commencement of treatment or at autopsy, the case
raises questions regarding the stratification of adjuvant
treatments for which no current evidence exists in an
outwardly healthy group. While currently available data
suggests such reactions are likely to be extremely rare,
we would urge clinicians to be vigilant as to possible sor-
afenib DILI and ensure suspected cases are reported.
We suggest that future trial-wide genetic profiling of
patients may potentially expedite identification of mar-
kers of idiosyncratic drug reaction to novel oncological
agents, including those denoting HLA allele status [20],
permitting genotype based risk stratification.
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